LCTX
AMEX · Biotechnology
Lineage Cell Therapeutics In
$0.99
-0.04 (-3.45%)
Open$1.04
Previous Close$1.03
Day High$1.04
Day Low$0.98
52W High$2.09
52W Low$0.88
Volume—
Avg Volume1.27M
Market Cap254.17M
P/E Ratio—
EPS$-0.14
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+3,964.4% upside
Current
$0.99
$0.99
Target
$40.42
$40.42
$29.91
$40.42 avg
$53.83
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 13.17M | 8.17M | 231.61M |
| Net Income | -70,176,889 | -39,200,099 | -65,233,876 |
| Profit Margin | -240.2% | -228.2% | -28.2% |
| EBITDA | -39,676,249 | -23,394,014 | -95,106,936 |
| Free Cash Flow | — | — | -33,113,271 |
| Rev Growth | +61.1% | +61.1% | -6.2% |
| Debt/Equity | 0.00 | 0.00 | 0.70 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $288.24 | -2.24% | 81.4 | 513.86B |
| AMGN | Amgen Inc | $460.28 | -3.80% | 28.5 | 249.09B |
| GILD | Gilead Sciences Inc | $167.57 | -3.96% | — | 212.04B |
| VRTX | Vertex Pharmaceuticals Inc | $542.50 | -1.19% | 30.6 | 134.77B |
| REGN | Regeneron Pharmaceuticals | $902.90 | -2.98% | 19.5 | 84.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.66 | -2.74% | 28.8 | 23.28B |